scholarly journals Fibronectin concentration in plasma of patients with breast cancer, colon cancer, and acute leukemia

Cancer ◽  
1983 ◽  
Vol 51 (6) ◽  
pp. 1142-1147 ◽  
Author(s):  
Jennifer J. Choate ◽  
Deane F. Mosher
Biomolecules ◽  
2020 ◽  
Vol 10 (2) ◽  
pp. 237 ◽  
Author(s):  
Barnali Deb ◽  
Pratyay Sengupta ◽  
Janani Sambath ◽  
Prashant Kumar

Tumor heterogeneity attributes substantial challenges in determining the treatment regimen. Along with the conventional treatment, such as chemotherapy and radiotherapy, targeted therapy has greater impact in cancer management. Owing to the recent advancements in proteomics, we aimed to mine and re-interrogate the Clinical Proteomic Tumor Analysis Consortium (CPTAC) data sets which contain deep scale, mass spectrometry (MS)-based proteomic and phosphoproteomic data sets conducted on human tumor samples. Quantitative proteomic and phosphoproteomic data sets of tumor samples were explored and downloaded from the CPTAC database for six different cancers types (breast cancer, clear cell renal cell carcinoma (CCRCC), colon cancer, lung adenocarcinoma (LUAD), ovarian cancer, and uterine corpus endometrial carcinoma (UCEC)). We identified 880 phosphopeptide signatures for differentially regulated phosphorylation sites across five cancer types (breast cancer, colon cancer, LUAD, ovarian cancer, and UCEC). We identified the cell cycle to be aberrantly activated across these cancers. The correlation of proteomic and phosphoproteomic data sets identified changes in the phosphorylation of 12 kinases with unchanged expression levels. We further investigated phosphopeptide signature across five cancer types which led to the prediction of aurora kinase A (AURKA) and kinases-serine/threonine-protein kinase Nek2 (NEK2) as the most activated kinases targets. The drug designed for these kinases could be repurposed for treatment across cancer types.


Author(s):  
Ajay Kumar ◽  
Salahuddin ◽  
Avijit Mazumder ◽  
Mohammad Shahar Yar ◽  
Rajnish Kumar ◽  
...  

Abstract: New drugs introduced on the market each year have privileged structures specifically for anticancer targets, of which quinoline-based analogues also play an important role. This review lit up quinoline and its derivatives, which have great potency against various cancer cells including prostate cancer, breast cancer, colon cancer, pancreas cancer and many more. This review describes the most likely process-scale synthetic approaches of quinoline and its derivatives having specific pharmacophore, for anticancer targets along. It is also described the undergoing development and recently approved drugs in tabular form. Quinoline moiety as privileged structural pharmacophore has most effective activity against different cancer cell lines like prostate cancer, breast cancer, stomach cancer, pancreas cancer, Colon cancer, CNS cancer and renal cancer. Because of this advantage, it has the potency to grow with new research works about the anticancer as well as enhancing the value of the investigative process in the field of medicinal chemistry by introducing new effective alignments of substituents. It can be used as lead compounds for further research in the subject of anticancer drug discovery.


Author(s):  
Robert D. Ficalora

Chapter 8 presents multiple-choice, board review questions on oncology including lung cancer, colon cancer, ovarian cancer, breast cancer, and prostate cancer. Full explanations are provided with the correct answers.


2019 ◽  
Vol 78 (1) ◽  
pp. 1-18 ◽  
Author(s):  
Khemayanto Hidayat ◽  
Hui-Juan Zhou ◽  
Bi-Min Shi

Abstract Context Excess weight has been linked to increased risks of 13 types of cancers. Physical activity is a non-nutritional modifiable lifestyle factor that is not only crucial for weight control but is also known to regulate hormones and metabolic pathways that may contribute to carcinogenesis. There is solid evidence that being physically active during middle and late adulthood lowers the risks of 3 obesity-related cancers, namely breast cancer, colon cancer, and endometrial cancer. However, the associations between physical activity at a young age (childhood, adolescence, and young adulthood; age 5 to ≤30 yr) and lifetime physical activity and the risks of breast cancer, colon cancer, and endometrial cancer are less defined. Objective The present systematic review and meta-analysis of observational studies was performed in accordance with the MOOSE guidelines to determine whether physical activity at a young age and lifetime physical activity may lower the risks of breast cancer, colon cancer, and endometrial cancer. Data sources The PubMed and Web of Science databases were searched for relevant observational studies published from inception to July 2018. Study selection Observational studies (prospective cohort, case-cohort, nested case-control, historical cohort, and case-control) were considered relevant if they investigated the association between physical activity at a young age or lifetime physical activity and the risks of developing selected cancers. Data extraction A random-effects meta-analysis was performed to generate the summary relative risk (RR) with 95%CI for the highest vs the lowest category of physical activity of any type. Results Eighty publications were included in the present meta-analysis. Higher physical activity at a young age was associated with lower risks of breast cancer (RR 0.81, 95%CI 0.76, 0.87) and colon cancer (RR 0.67, 95%CI 0.50, 0.88). Similarly, lifetime physical activity was inversely associated with the risks of breast cancer (RR 0.79, 95%CI 0.72, 0.86) and colon cancer (RR 0.75, 95%CI 0.69, 0.82). For breast cancer, menopausal status did not appear to modify the observed inverse association. The benefit with respect to endometrial cancer risk reduction was only observed with higher lifetime physical activity (RR 0.77, 95%CI 0.67, 0.88), not with higher physical activity at a young age (RR 0.89, 95%CI 0.73, 1.07). Conclusions Being physically active over a lifetime, starting from early childhood, may lower the risks of developing breast cancer, colon cancer, and endometrial cancer.


Nutrients ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 3927
Author(s):  
So Young Kim ◽  
Dae Myoung Yoo ◽  
Chanyang Min ◽  
Hyo Geun Choi

Although the effects of coffee consumption and physical exercise on the risk of cancer have been suggested, their interactions have not been investigated. The present cross-sectional study aimed to investigate the correlation of coffee consumption and physical exercise with cancer. Participants ≥40 years old in the Korean Genome and Epidemiology Study 2004–2016 were included (n = 162,220). Histories of gastric cancer, hepatic cancer, colon cancer, breast cancer, uterine cervix cancer, lung cancer, thyroid cancer, prostate cancer, and bladder cancer were analyzed according to the coffee consumption groups using logistic regression models. The odds among individuals in the >60 cups/month coffee group were lower for gastric cancer (adjusted odds ratio (aOR) = 0.80 (95% confidence intervals = 0.65–0.98)), hepatic cancer (0.32 (0.18–0.58)), colon cancer (0.53 (0.39–0.72)), breast cancer (0.56 (0.45–0.70)), and thyroid cancer (0.71 (0.59–0.85)) than for individuals in the no coffee group. Physical exercise of ≥150 min/week was correlated with higher odds for gastric cancer (1.18 (1.03–1.36)), colon cancer (1.52 (1.26–1.83)), breast cancer (1.53 (1.35–1.74)), thyroid cancer (1.42 (1.27–1.59)), and prostate cancer (1.61 (1.13–2.28)) compared to no exercise. Coffee consumption and physical exercise showed an interaction in thyroid cancer (p = 0.002). Coffee consumption was related to a decreased risk of gastric cancer, hepatic cancer, colon cancer, breast cancer, and thyroid cancer in the adult population. Physical exercise was positively correlated with gastric cancer, colon cancer, breast cancer, thyroid cancer, and prostate cancer.


Author(s):  
Marina Kochiyeva

Data on modern methodological approaches that are used in screening for cancer are summarized. General principles of organizing screening studies are examined from the perspective of evidence-based medicine, target population, research methods, and effectiveness of the implemented screening programs for breast cancer, cervical cancer, and colon cancer are determined.


Sign in / Sign up

Export Citation Format

Share Document